Then, LMB-100 (also known as RG7787) was generated by fusing an anti-MSLN Fab to PE24, retaining the same anti-tumor effectiveness as SS1P but with reduced side effects [126, 127]. The gene discussed is MSLN; the disease is neoplasm.